Loading…
This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.
Lobbying Spend
$946K
Filings
36
Firms Hired
2
Active Period
2005–2010
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Community-Based Mental Health Infrastructure Improvements Act
2010 · third_quarter · Firm: K&L GATES LLP
Matters generally related to biomedical vaccines, biomedical therapeutics, biodefense, and pandemic preparedness; general interest in H.R. 5498, the WMD Prevention and Preparedness Act of 2010; section 4155 of the House amendment to the Senate-passed version of H.R. 4899 which would have transferred funding out of the BioShield Special Reserve Fund.
Client expense: — · Firm income: $40,000
Matched citations: H.R. 4899
WMD Prevention and Preparedness Act of 2010
2010 · third_quarter · Firm: K&L GATES LLP
Matters generally related to biomedical vaccines, biomedical therapeutics, biodefense, and pandemic preparedness; general interest in H.R. 5498, the WMD Prevention and Preparedness Act of 2010; section 4155 of the House amendment to the Senate-passed version of H.R. 4899 which would have transferred funding out of the BioShield Special Reserve Fund.
Client expense: — · Firm income: $40,000
Matched citations: H.R. 5498
Community-Based Mental Health Infrastructure Improvements Act
2010 · third_quarter · Firm: K&L GATES LLP
Matters generally related to biomedical vaccines, biomedical therapeutics, biodefense, and pandemic preparedness; general interest in H.R. 5498, the WMD Prevention and Preparedness Act of 2010; section 4155 of the House amendment to the Senate-passed version of H.R. 4899 which would have transferred funding out of the BioShield Special Reserve Fund.
Client expense: — · Firm income: $40,000
Matched citations: H.R. 4899
WMD Prevention and Preparedness Act of 2010
2010 · third_quarter · Firm: K&L GATES LLP
Matters generally related to biomedical vaccines, biomedical therapeutics, biodefense, and pandemic preparedness; general interest in H.R. 5498, the WMD Prevention and Preparedness Act of 2010; section 4155 of the House amendment to the Senate-passed version of H.R. 4899 which would have transferred funding out of the BioShield Special Reserve Fund.
Client expense: — · Firm income: $40,000
Matched citations: H.R. 5498
WMD Prevention and Preparedness Act of 2010
2010 · second_quarter · Firm: K&L GATES LLP
Matters generally related to biomedical vaccines, biomedical therapeutics, biodefense, and pandemic preparedness; general interest in H.R. 5498, the WMD Prevention and Preparedness Act of 2010.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 5498
American Recovery and Reinvestment Act of 2009
2009 · third_quarter · Firm: K&L GATES LLP
H.R. 1 and S. 336; matters related to biomedical vaccines, biomedical therapeutics, biodefense, and pandemic preparedness.
Client expense: — · Firm income: $60,000
Matched citations: S. 336
American Recovery and Reinvestment Act of 2009
2009 · third_quarter · Firm: CANGENE CORPORATION
H.R. 1 & S. 336: matters related to biomedical vaccines, biomedical therapeutics, biodefense and pandemic preparedness.
Client expense: $80,000 · Firm income: —
Matched citations: S. 336
American Recovery and Reinvestment Act of 2009
2009 · second_quarter · Firm: K&L GATES LLP
H.R. 1 and S. 336; matters related to biomedical vaccines, biomedical therapeutics, biodefense, and pandemic preparedness.
Client expense: — · Firm income: $60,000
Matched citations: S. 336
American Recovery and Reinvestment Act of 2009
2009 · second_quarter · Firm: CANGENE CORPORATION
H.R. 1 & S. 336: matters related to biomedical vaccines, biomedical therapeutics, biodefense and pandemic preparedness.
Client expense: $100,000 · Firm income: —
Matched citations: S. 336
American Recovery and Reinvestment Act of 2009
2009 · first_quarter · Firm: K&L GATES LLP
H.R. 1 and S. 336; matters related to biomedical vaccines, biomedical therapeutics, biodefense, and pandemic preparedness.
Client expense: — · Firm income: $70,000
Matched citations: S. 336
American Recovery and Reinvestment Act of 2009
2009 · first_quarter · Firm: CANGENE CORPORATION
H.R. 1 & S. 336: mattes related to biomedical vaccines, biomedical therapeutics, biodefense and pandemic preparedness.
Client expense: $90,000 · Firm income: —
Matched citations: S. 336
Department of Veterans Affairs Claims Backlog Reduction Act of 2002
2006 · year_end · Firm: K&L GATES LLP
HR 5533, S 2564, and S 3678, BioShield II legislation. Monitor legislation regarding biodefense vaccines and therapeutics, and preparation for possible pandemic. Discuss possible changes to the provisions of S 2564 and S 3678 to address procurement concerns.
Client expense: — · Firm income: $100,000
Matched citations: HR 5533
Biodefense and Pandemic Vaccine and Drug Development Act of 2006
2006 · year_end · Firm: K&L GATES LLP
HR 5533, S 2564, and S 3678, BioShield II legislation. Monitor legislation regarding biodefense vaccines and therapeutics, and preparation for possible pandemic. Discuss possible changes to the provisions of S 2564 and S 3678 to address procurement concerns.
Client expense: — · Firm income: $100,000
Matched citations: S 2564
HR 5533, S 2564, and S 3678, BioShield II legislation. Monitor legislation regarding biodefense vaccines and therapeutics, and preparation for possible pandemic. Discuss possible changes to the provisions of S 2564 and S 3678 to address procurement concerns.
Client expense: — · Firm income: $100,000
Matched citations: S 3678
Department of Veterans Affairs Claims Backlog Reduction Act of 2002
2006 · year_end · Firm: CANGENE CORPORATION
HR 5533, S 2564, and S 3678, BioShield II legislation. Monitor legislation regarding biodefense vaccines and therapeutics, and preparation for possible pandemic. Discuss possible changes to provisions of S 2564 and S 3678 to address procurement concerns.
Client expense: — · Firm income: —
Matched citations: HR 5533
Biodefense and Pandemic Vaccine and Drug Development Act of 2006
2006 · year_end · Firm: CANGENE CORPORATION
HR 5533, S 2564, and S 3678, BioShield II legislation. Monitor legislation regarding biodefense vaccines and therapeutics, and preparation for possible pandemic. Discuss possible changes to provisions of S 2564 and S 3678 to address procurement concerns.
Client expense: — · Firm income: —
Matched citations: S 2564
Pandemic and All-Hazards Preparedness Act
2006 · year_end · Firm: CANGENE CORPORATION
HR 5533, S 2564, and S 3678, BioShield II legislation. Monitor legislation regarding biodefense vaccines and therapeutics, and preparation for possible pandemic. Discuss possible changes to provisions of S 2564 and S 3678 to address procurement concerns.
Client expense: — · Firm income: —
Matched citations: S 3678
Protecting America in the War on Terror Act of 2005
2005 · mid_year · Firm: K&L GATES LLP
S.3, S. 975, BioShield II legislation. Monitor legislation regarding biodefense vaccines and therapeutics.
Client expense: — · Firm income: $60,000
Matched citations: S.3
Protecting America in the War on Terror Act of 2005
2005 · mid_year · Firm: K&L GATES LLP
S. 3, S. 975, BioShield II legislation. Monitor legislation regarding biodefense vaccines and therapeutics.
Client expense: — · Firm income: $60,000
Matched citations: S. 3
S. 3, S. 975, BioShield II legislation. Monitor legislation regarding biodefense vaccines and therapeutics.
Client expense: — · Firm income: $60,000
Matched citations: S. 975
S.3, S. 975, BioShield II legislation. Monitor legislation regarding biodefense vaccines and therapeutics.
Client expense: — · Firm income: $60,000
Matched citations: S. 975
Source: Senate LDA